301 related articles for article (PubMed ID: 36844142)
1. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.
Brzdęk M; Zarębska-Michaluk D; Invernizzi F; Cilla M; Dobrowolska K; Flisiak R
World J Gastroenterol; 2023 Feb; 29(6):949-966. PubMed ID: 36844142
[TBL] [Abstract][Full Text] [Related]
2. Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.
Brzdęk M; Zarębska-Michaluk D; Rzymski P; Lorenc B; Kazek A; Tudrujek-Zdunek M; Janocha-Litwin J; Mazur W; Dybowska D; Berak H; Parfieniuk-Kowerda A; Klapaczyński J; Sitko M; Sobala-Szczygieł B; Piekarska A; Flisiak R
World J Gastroenterol; 2023 Apr; 29(13):2015-2033. PubMed ID: 37155527
[TBL] [Abstract][Full Text] [Related]
3. Genotype 3-hepatitis C virus' last line of defense.
Zarębska-Michaluk D
World J Gastroenterol; 2021 Mar; 27(11):1006-1021. PubMed ID: 33776369
[TBL] [Abstract][Full Text] [Related]
4. Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.
Zarębska-Michaluk D; Brzdęk M; Jaroszewicz J; Tudrujek-Zdunek M; Lorenc B; Klapaczyński J; Mazur W; Kazek A; Sitko M; Berak H; Janocha-Litwin J; Dybowska D; Supronowicz Ł; Krygier R; Citko J; Piekarska A; Flisiak R
World J Gastroenterol; 2022 Dec; 28(45):6380-6396. PubMed ID: 36533109
[TBL] [Abstract][Full Text] [Related]
5. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
Nordien R; Sonderup MW; Spearman CW
S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679
[TBL] [Abstract][Full Text] [Related]
6. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Dobrowolska K; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Stępień P; Zarębska-Michaluk D
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062302
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and antiviral therapy in patients infected with hepatitis C virus in the interferon‑free era.
Brzdęk M; Dobrowolska K; Pabjan P; Zarębska-Michaluk D
Pol Arch Intern Med; 2022 Sep; 132(9):. PubMed ID: 35938950
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hepatitis C: a systematic review.
Kohli A; Shaffer A; Sherman A; Kottilil S
JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
[TBL] [Abstract][Full Text] [Related]
9. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C therapy: Looking toward interferon-sparing regimens.
Au TH; Destache CJ; Vivekanandan R
J Am Pharm Assoc (2003); 2015; 55(2):e72-84; quiz e85-6. PubMed ID: 25658389
[TBL] [Abstract][Full Text] [Related]
11. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
12. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
[TBL] [Abstract][Full Text] [Related]
13. Genotype 4 hepatitis C virus-a review of a diverse genotype.
Brzdęk M; Dobrowolska K; Flisiak R; Zarębska-Michaluk D
Adv Med Sci; 2023 Mar; 68(1):54-59. PubMed ID: 36640687
[TBL] [Abstract][Full Text] [Related]
14. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders.
Sharafi H; Behnava B; Azizi-Saraji A; Namvar A; Anvar A; Salimi S; Alavian SM
Virol J; 2021 Oct; 18(1):199. PubMed ID: 34620204
[TBL] [Abstract][Full Text] [Related]
16. Interferon-containing and interferon-free HCV therapy for HIV-infected patients.
Sulkowski MS
Semin Liver Dis; 2014 Feb; 34(1):72-8. PubMed ID: 24782260
[TBL] [Abstract][Full Text] [Related]
17. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
18. Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings.
Pabjan P; Brzdęk M; Chrapek M; Dziedzic K; Stępień PM; Paluch K; Garbat A; Błoniarczyk P; Reczko K; Zarębska-Michaluk D
Pol Arch Intern Med; 2021 Nov; 131(11):. PubMed ID: 34565137
[TBL] [Abstract][Full Text] [Related]
19. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
[TBL] [Abstract][Full Text] [Related]
20. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients.
Ebid AIM; Ahmed OA; Agwa SH; Abdel-Motaleb SM; Hagag RS
Int J Clin Pharm; 2020 Aug; 42(4):1207-1216. PubMed ID: 32712884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
